SETD4 and adrenal cortex carcinoma: As a result, we deduced that LIHC, ACC, HNSC, DLBC, and KICH patients with elevated SETD4 levels may benefit from treatment with platinum‐based chemotherapeutic drugs or PARP inhibitors.